Integra LifeSciences (NASDAQ:IART) Upgraded to “Neutral” by Citigroup

Integra LifeSciences (NASDAQ:IARTGet Free Report) was upgraded by stock analysts at Citigroup from a “sell” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, MarketBeat reports. The firm currently has a $38.00 price objective on the life sciences company’s stock. Citigroup’s price target would indicate a potential upside of 13.37% from the company’s previous close.

A number of other equities research analysts also recently commented on the stock. JMP Securities reduced their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research report on Thursday, February 29th. Truist Financial dropped their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Wells Fargo & Company raised shares of Integra LifeSciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $40.00 to $49.00 in a report on Tuesday, December 5th. Finally, StockNews.com raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Thursday, March 28th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $44.89.

Read Our Latest Research Report on Integra LifeSciences

Integra LifeSciences Stock Down 3.5 %

Integra LifeSciences stock opened at $33.52 on Wednesday. The firm has a market capitalization of $2.63 billion, a P/E ratio of 40.39, a P/E/G ratio of 1.05 and a beta of 1.12. The stock’s fifty day simple moving average is $39.01 and its 200-day simple moving average is $39.60. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94. Integra LifeSciences has a twelve month low of $33.24 and a twelve month high of $59.33.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business had revenue of $397.00 million during the quarter, compared to analysts’ expectations of $399.30 million. During the same period last year, the company earned $0.94 EPS. The business’s quarterly revenue was down .3% compared to the same quarter last year. As a group, equities analysts expect that Integra LifeSciences will post 3.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds have recently made changes to their positions in the stock. Signaturefd LLC boosted its holdings in shares of Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after purchasing an additional 415 shares during the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after acquiring an additional 370 shares in the last quarter. Itau Unibanco Holding S.A. lifted its holdings in shares of Integra LifeSciences by 469.5% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock valued at $31,000 after acquiring an additional 615 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Integra LifeSciences during the 3rd quarter valued at $47,000. Finally, Covestor Ltd lifted its holdings in shares of Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 921 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

(Get Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Further Reading

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.